Maintenance Therapy in the Management of Multiple Myeloma
Release Date: March 15, 2012
Expiration Date: March 15, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to destruction of bone as well as marrow failure. Presenting a challenge to both academic- and community-based oncologists who treat many kinds of malignancies, MM is a relatively small population cancer with only some 20,000 patients diagnosed annually. Consequently, many practitioners may have comparatively little direct experience with the appropriate management of patients with this disease. While the introduction of novel agents like bortezomib, lenalidomide, and thalidomide have significantly increased life expectancy and quality of life for MM patients, multiple myeloma remains incurable at this time and all patients will eventually relapse. The best prognosis for a patient with MM is prior to becoming relapsed/refractory. Maintenance therapy has been proposed to provide more enduring response as well as improved survival compared to those achieved through primary therapy alone. The benefits of maintenance therapy have been clinically observed both in patients who have undergone autologous stem cell transplant (ASCT) as well as in elderly patients who are ineligible for ASCT. While none of the novel agents (thalidomide, lenalidomide or bortezomib) are currently approved by the FDA for maintenance therapy in the treatment of MM, the most recent NCCN guidelines for multiple myeloma have listed two new options, lenalidomide and bortezomib as preferred options for maintenance therapy in addition to thalidomide. Clinical trials are ongoing exploring the efficacy and safety of a number of maintenance regimens with various novel therapies and in different MM patient populations with promising results.
Dr. Antonio Palumbo, member of the Italian Multiple Myeloma Study Group and professor at the Molinette Hospital in Turin, Italy, invites you to join him in this exciting grand rounds discussion regarding the considerations in practice for maintenance therapy in multiple myeloma.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the treatment of multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify agents currently recommended by the National Comprehensive Cancer Network (NCCN) for maintenance therapy in patients with MM
- Describe current clinical efficacy and safety data for maintenance therapy regimens used in transplant-eligible and transplant-ineligible MM patients
- Describe the role of maintenance therapy in achieving therapeutic goals in the management of MM
Maintenance Therapy in the Management of Multiple Myeloma – Antonio Palumbo, MD
Instructions for Participation and Credit
This activity is eligible for credit through March 15, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Antonio Palumbo, MD
Chief, Myeloma Unit
Department of Oncology
University of Torino
Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. Before his current position as chief of the Myeloma Unit of the Department of Oncology, Section of Hematology at the University of Torino, Dr. Palumbo was a research associate at the Wistar Institute, University of Pennsylvania.
In addition to membership in numerous professional organizations, including the Italian Society of Hematology, Italian Society of Experimental Hematology, European Society of Hematology, American Society of Hematology, and the American Society of Clinical Oncology, Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 150 publications in peer-reviewed journals as well numerous abstract and several textbooks chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia, his current research focuses on the pathogenesis and treatment of multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-304-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Antonio Palumbo has received honoraria related to formal advisory activities from Celgene Corporation and Janssen-Cilag EMEA, as well as honoraria related to speakers’ bureau activities from Merck & Co., Inc. and Amgen Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene Tombler, PhD, medical director-oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Palumbo has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Palumbo has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.